Cantargia AB (publ) (OM: CANTA)
Health Care · Biotechnology · SE
Skr1.31
-4.67% today · -46.6% 1Y
Cantargia AB (publ) (OM: CANTA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $37.18M and employs 22 people.
Over the last twelve months the share price has lost 46.6%, trading between 1.25 and 6.59.
Tweenvest scores Cantargia AB (publ) across four factors: quality 77/100, value 26/100. Its strongest factor is quality.
CANTA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $37.18M
- Revenue (TTM)
- $32.74M
- P/E
- 1.95
- EPS
- 0.67
- Dividend yield
- —
- Beta (5Y)
- 1.56
- 52-week high
- Skr6.59
- 52-week low
- Skr1.25
- Avg volume (3M)
- —
- Shares outstanding
- 281.94M
- Employees
- 22
- Next earnings
- —
About Cantargia AB (publ)
Cantargia AB (publ), a biotechnology company established in Lund, Sweden, in 2010, is dedicated to the research and development of antibody-driven therapies for severe illnesses. Its lead product, CAN04, is an antibody specifically engineered to target Interleukin-1 Receptor Accessory Protein (IL1RAP). This innovative treatment aims to identify and stimulate the immune system to destroy cancer cells, while also mitigating tumor-related inflammation fueled by the Interleukin-1 system, and is currently in Phase IIa clinical trials. The company is also advancing CAN10, another IL1RAP-specific antibody, through preclinical development for autoimmune and inflammatory conditions like systemic sclerosis and myocarditis. Additionally, Cantargia is exploring other CANxx antibodies that also interact with IL1RAP. The manufacturing and production of CAN04 are facilitated through partnerships with Patheon Biologics BV and BioWa Inc., and its clinical study is supported by Specialized Medical Services-oncology BV.
- ISIN
- SE0006371126
- Founded
- 2009
- Listed since
- Mar 17, 2015
- Exchange
- OMX Nordic Exchange Stockholm
- Currency
- SEK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| eXoZymes, Inc.NasdaqCM: EXOZ | $37.96M | $4.09 | -22.10% |
| BrightPath Biotherapeutics Co., Ltd.TSE: 4594 | $37.83M | ¥43.00 | -4.44% |
| Sprint Bioscience AB (publ)OM: SPRINT | $37.82M | Skr3.55 | -2.74% |
| Novacyt S.A.ENXTPA: ALNOV | $37.20M | €0.46 | -1.08% |
| NeoCore Technology Co., Ltd.TPEX: 4131 | $37.10M | NT$30.20 | -3.21% |
| Enimmune CorporationTPEX: 6564 | $36.35M | NT$16.35 | -0.61% |
| Mendus AB (publ)OM: IMMU | $36.16M | Skr5.40 | -6.09% |
| Actinium Pharmaceuticals, Inc.NYSEAM: ATNM | $35.53M | $1.13 | +2.73% |
Figures last refreshed Oct 18, 2026.